← Back to Search

Alkylating agents, Anti-tumor antibiotic, Anti-metabolites

Chemotherapy + Radiation for Lung Cancer

Phase 2

Waitlist Available

Research Sponsored by Baptist Health South Florida

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

No evidence of hematogenous metastases

No intrathoracic tumor recurrence following resection

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is studying how well combination chemotherapy and specialized high-dose radiation therapy work in treating patients with stage II or stage III non-small cell lung cancer.

Who is the study for?

This trial is for adults with stage II or III non-small cell lung cancer that can't be surgically removed. They must have certain blood, liver, and kidney function levels, no recent heart issues, and not have had chemotherapy or thoracic/neck radiation before. Weight loss should be under 5% in the past 3 months.Check my eligibility

What is being tested?

The study tests a combination of chemotherapy drugs and specialized high-dose radiation therapy to see if they are effective at treating this type of lung cancer by stopping tumor growth or killing tumor cells while minimizing damage to healthy tissue.See study design

What are the potential side effects?

Chemotherapy may cause nausea, fatigue, hair loss, increased risk of infection due to low blood counts. Radiation therapy might lead to skin irritation at the treatment site, tiredness, and potential damage to nearby organs like the lungs.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My cancer has not spread through my bloodstream.

Select...

My lung cancer has not returned after surgery.

Select...

My cancer is at stage II, IIIA, or IIIB.

Select...

I do not have fluid in my lungs, except if it's after chest surgery.

Select...

I am 18 years old or older.

Select...

I do not experience chest pain.

Select...

I do not have congestive heart failure.

Select...

My heart rhythm is stable without any uncontrolled irregularities.

Select...

My lung cancer has not been surgically removed and is advanced but not spread far.

Select...

I am mostly able to care for myself and carry out daily activities.

Select...

I do not have any heart problems that cause symptoms.

Select...

My heart pumps blood well.

Select...

I haven't had any cancer except for skin cancer in the last 3 years.

Select...

I have not had a heart attack in the last 6 months.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 14Eligibility criteria met

Find a Location

Who is running the clinical trial?

Baptist Health South FloridaLead Sponsor

48 Previous Clinical Trials

7,831 Total Patients Enrolled

Andre A. Abitbol, MDStudy ChairBaptist Health South Florida

1 Previous Clinical Trials

36 Total Patients Enrolled

Media Library

Combination Chemotherapy (Alkylating agents, Anti-tumor antibiotic, Anti-metabolites) Clinical Trial Eligibility Overview. Trial Name: NCT00004253 — Phase 2

Lung Cancer Clinical Trial 2023: Combination Chemotherapy Highlights & Side Effects. Trial Name: NCT00004253 — Phase 2

Combination Chemotherapy (Alkylating agents, Anti-tumor antibiotic, Anti-metabolites) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00004253 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this trial still open to enrolling participants?

"According to clinicaltrials.gov, this research study is not presently enrolling patients for participation. It was initially listed on March 1st 2000 and last updated on December 17th 2013; however, there are 2041 other trials currently recruiting participants."

Answered by AI

Has this intervention been given the green light by the FDA?

"Our risk assessment indicates that the safety of this treatment is a 2, as there exists clinical evidence to support its safety but not yet efficacy."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery

2000. "Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00004253.

All > Lung > Sclc